Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Hacia un manejo clínico personalizado de pacientes oncológicos con fracaso renal agudo asociado a los immune-checkpoint inhibitors (ICIs)

IP: Maria Jose Soler Romeo
Collaborators: Enriqueta Felip Font, Oriol Bestard Matamoros, Sheila Bermejo Garcia, Concepció Jacobs Cachá, Elena Isabel Crespo Gimeno, Sara Nuñez Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 246840
Reference: AC22/00029
Duration: 01/01/2023 - 31/12/2025

Nefrologia i Trasplantament Renal

IP: Oriol Bestard Matamoros
Collaborators: Marina Lopez Martinez, Francesc Moreso Mateos, Natalia Ramos Terrades, Maria Jose Soler Romeo, Joana Sellarés Roig, Pamela Dominguez Baez, Irene Agraz Pamplona, Sheila Bermejo Garcia, Mariona Juvé Torres, Irina Betsabe Torres Rodriguez, Concepció Jacobs Cachá, Elena Isabel Crespo Gimeno, Laura Donadeu Casassas, Carmen Llorens Cebriá, Manel Perelló Carrascosa, Maria Antonia Emilia Meneghini
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00883
Duration: 01/01/2022 - 30/06/2025

Desentrañando las vías protectoras de los SGLT2i y GLP-1RA en la enfermedad renal diabética: papel de las proteínas adaptadoras MAP17 y D-AKAP-2 en ratones db/db y organoides renales humanos.

IP: Maria Jose Soler Romeo
Collaborators: Mario Alonso Narvaez Barros, Pamela Dominguez Baez, Sheila Bermejo Garcia, Alejandra Planas Vilaseca, Concepció Jacobs Cachá, Juan Carlos León Román, Irene Martinez Diaz
Funding agency: Instituto de Salud Carlos III
Funding: 122210
Reference: PI21/01292
Duration: 01/01/2022 - 30/06/2026

RICORS2040 - Inflamación e inmunopatología de órganos y sistemas

IP: Maria Jose Soler Romeo
Collaborators: Francesc Moreso Mateos, Oriol Bestard Matamoros, Joana Sellarés Roig, Irina Betsabe Torres Rodriguez, Concepció Jacobs Cachá, Maria Antonia Emilia Meneghini
Funding agency: Instituto de Salud Carlos III
Funding: 105765
Reference: RD21/0005/0016
Duration: 01/01/2022 - 31/12/2024

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Jorge Pamias Romero

Jorge Pamias Romero

New Technologies and Craniofacial Microsurgery
Read more
Olga Luengo Sanchez

Olga Luengo Sanchez

Systemic Diseases
Read more
Anna Salo Rovira

Anna Salo Rovira

Research technician
Childhood Cancer and Blood Disorders
Read more
Estefania De la Torre Villaescusa

Estefania De la Torre Villaescusa

Head of unit
Teaching Unit
Internal Strategy Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.